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Abstract
Variant CJD (vCJD) is an incurable, infectious human disease, likely arising from the consumption of BSE-contaminated meat
products. Whilst the epidemic appears to be waning, there is much concern that vCJD infection may be perpetuated in
humans by the transfusion of contaminated blood products. Since 2004, several cases of transfusion-associated vCJD
transmission have been reported and linked to blood collected from pre-clinically affected donors. Using an animal model in
which the disease manifested resembles that of humans affected with vCJD, we examined which blood components used in
human medicine are likely to pose the greatest risk of transmitting vCJD via transfusion. We collected two full units of blood
from BSE-infected donor animals during the pre-clinical phase of infection. Using methods employed by transfusion services
we prepared red cell concentrates, plasma and platelets units (including leucoreduced equivalents). Following transfusion,
we showed that all components contain sufficient levels of infectivity to cause disease following only a single transfusion
and also that leucoreduction did not prevent disease transmission. These data suggest that all blood components are
vectors for prion disease transmission, and highlight the importance of multiple control measures to minimise the risk of
human to human transmission of vCJD by blood transfusion.
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Introduction
Human transmissible spongiform encephalopathies (TSEs),
including vCJD, are characterised by vacuolar pathology in brain,
alongside accumulation of a pathological form (PrPSc) of the prion
protein in neuronal and lymphoid tissues. Affected individuals
usually exhibit a long period of asymptomatic infection followed
by a shorter clinical phase. To date, there have been 174 cases of
vCJD in the UK and a further 52 cases worldwide, the majority of
which are thought to have been acquired directly from bovine
sources [1,2,3]. As disease diagnosis is usually confirmed post
mortem, typically by the detection of abnormal prion protein in
neuronal or lymphoid tissues [4,5], the prevalence of sub-clinical
infection is of major concern and predicting the number of vCJD
carriers is difficult. Current estimates suggest that between 1 in
4,000 to 1 in 10,000 people in the UK may be carriers of vCJD
infection [6,7,8]. The methionine (M) – valine (V) polymorphism
at codon 129 of the human prion protein gene (PRNP) is an
important determinant of susceptibility to vCJD and other human
TSEs. Although all clinical cases of vCJD have occurred in
individuals homozygous for methionine at codon 129 (MM129),
current clinical and experimental evidence indicates that individ-
uals of all PRNP genotypes are susceptible to vCJD infection
[9,10]. The pre-clinical phase of disease in individuals with the
MV129 or VV129 PRNP genotype is predicted to be longer than
those with the MM genotype; moreover these individuals may not
develop clinical disease but carry a subclinical infection and still
have the potential to transmit infection. Hence there is obvious
concern that human to human transmission from individuals sub-
clinically infected with vCJD may amplify or prolong a vCJD
outbreak in humans.
Of possible iatrogenic routes for human to human vCJD
transmission (which include surgical and dental instruments),
blood transfusion is of particular concern due to the widespread
distribution of infectivity in lymphoid tissues observed in vCJD
patients [11]. The potential sub-clinical prevalence of infection
among donors, combined with infectivity titres in blood and the
efficiency of blood as a route of transmission, are key factors which
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will influence the likelihood of acquiring vCJD by this route. To
date, there have been four vCJD infections associated with the
transfusion of non-leucoreduced red cell concentrates from donors
who later developed vCJD [12,13,14]. The UK blood services
have taken a number of measures to try to reduce the risk of
transmission of vCJD by blood, plasma and tissue products, such
as donor deferral, importation of plasma products and universal
leucoreduction of components [15].
Estimating the risk of disease transmission has relied on rodent
TSE models (infected intracerebrally [16,17,18,19,20,21,22]) to
predict the distribution and titre of prion-associated infectivity in
blood. Such experiments have suggested a titre of approximate-
ly10 infectious doses (ID)/ml in hamster blood [17,23]. However,
these models are not representative of the normal regimen of
transfusion in clinical settings, as the volumes that were
inoculated into brain were much lower than those that can be
transfused by the intravenous route. Sheep orally infected with
BSE provide an ideal model for studying transfusion-associated,
blood-borne vCJD in that the distribution of PrPSc and infectivity
in lymphoid tissues closely resembles that of vCJD patients [24].
Using this model, we were the first to show that prion diseases
(scrapie and experimental BSE infection in sheep) could be
transmitted via the transfusion of whole blood and buffy coat
[25,26,27]. Subsequently, other large animal transfusion models
have confirmed our findings [28,29,30]. A significant advantage
of using the sheep-BSE transfusion model is that blood from
sheep can be collected in similar volumes and processed to
equivalent specifications as human blood components, using the
same techniques employed in routine blood transfusion practice.
We have further exploited this valuable model and undertaken a
unique series of experiments to address the likelihood of
transmission of vCJD following the transfusion of blood
components used in clinical practice. Additionally we have
assessed the efficacy of leucoreduction in either reducing or
removing prion-associated infectivity in blood.
We report here, for the first time, several significant scientific
advances using this model. All non-leucodepleted components (i.e.
red cell concentrates, plasma units and platelet concentrates
prepared to the specification used in a clinical setting) from BSE-
infected animals are capable of causing prion disease in transfused
recipients following a single transfusion. Transmission of disease
occurred from blood collected early in the pre-clinical phase of
disease. Moreover the process of leucofiltration of blood
components did not prevent disease transmission.
Methods
Ethics statement
All animal work was reviewed and approved by ethical review
panel at The Institute for Animal Health and The Roslin Institute
and conducted under the authority of Home Office Project
Licences (references:30/2282 and 60/4143 respectively).
In vivo work
Some of the methods used in this study have been described
elsewhere: genotyping; oral infection of donors; housing of sheep
and observation of clinical signs [27]; cross matching of blood
[25]; blood collection and transfusion of whole blood/components
[26]. Sheep (sourced from the DEFRA scrapie-free flock) were all
of the ARQ/ARQ PrP genotype (therefore susceptible to BSE
infection [25,31]) using the standard terminology for codons 136,
154 and 171. Individual animals differed in their genotype at other
polymorphic codons of the PrP gene.
Inoculation regime
To assess which clinically-relevant blood components have the
potential to cause prion disease following transfusion, we first
orally infected 40 TSE-free donor sheep (of the susceptible ARQ/
ARQ PrP genotype) with 5 g of bovine BSE-infected brain
homogenate. Groups of inoculations were performed at monthly
intervals (typically eight sheep at a time) starting in September
2006 and continuing until February 2007. Of the 40 BSE-
inoculated sheep, one died of intercurrent cause before blood
could be collected for transfusion and therefore was excluded from
the study. Mock-infected donors were inoculated with 5 g normal
bovine brain homogenate at similar time intervals as the infected
cohort (Figure 1).
PrPSc detection
The preparation of brain/peripheral tissue homogenates for
PrPSc detection (using Proteinase K (PK) digestion and sodium
Figure 1. Overview of experimental design. Sheep used as BSE
blood donors were divided into two experimental groups (A and B),
though both groups were orally inoculated (inoc.) with 5 g of BSE brain
homogenate at approximately 3–6 months of age. Two units of blood
were collected from all BSE donors and processed according to the
experimental regime described: group A sheep - one unit was
transfused to recipients as whole blood, whereas blood from the
second unit was processed into components and then transfused. Both
units of blood from sheep in group B were separated into components
and one set of components was passed through human leucoreduction
(LR) filters prior to transfusion. Negative control donors (group C), were
orally inoculated with normal bovine brain homogenate (NBB). A unit of
whole blood was collected from these sheep and transfused to
recipients.
doi:10.1371/journal.pone.0023169.g001
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phosphotungstic acid (NaPTA) precipitation, gel electrophoresis
and Western blotting with the monoclonal antibody BC6 at a
concentration of 1 mg/ml) is described elsewhere [32]. A
proportion of the PK and NaPTA-treated brain homogenates
were deglycosylated using PNGaseF (New England Biolabs) using
established methods [33] with a modification to the amount of
enzyme added (typically 1500 U per reaction). Immunohisto-
chemistry using the antibody BG4 was undertaken as previously
described [25], with modification of the chromagen to Vector
NovaRED (Vector Laboratories). Tissues from all sheep (regard-
less of whether they died following clinical signs of BSE/
intercurrent causes or were culled for welfare reasons) were tested
using these methods.
Preparation of blood components for transfusion
Two units of whole blood (WB, 1 unit = 450 ml610% (v/v))
were collected from each donor sheep (where possible) into
quadruple, bottom and top (BAT) blood packs (Fresenius
Hemocare, NPBI) fitted with inline leucoreduction filters,
containing 63 ml of anti-coagulant CPD.A1 (citrate, phosphate,
dextrose, adenine). Approximately 1 ml was sampled from the
filled blood bags for analysis and then the majority of units (except
eight units of whole blood) were centrifuged for 7.5 min, 1350 g at
20uC (Sorvall RC3BP, H6000A rotor). This resulted in three
layers: the top layer was platelet-rich plasma (PRP), the interface
contained buffy coat (BC) and the lower layer contained red cells.
Each of these layers were extracted into empty, parallel blood
packs using a Compomat G4 optimised for the separation of sheep
blood components (Fresenius Hemocare, NPBI). Immediately
after separation, 100 ml of the preservative SAG-M (saline,
adenine, glucose and mannitol) was aseptically added to the red
cells, as a replacement for the loss of plasma during separation,
and thoroughly mixed. The PRP was centrifuged at 2350 g for
10 min at 22uC, yielding a platelet-poor plasma supernatant (the
plasma unit) and a platelet-rich plasma pellet (the platelet
concentrate). The plasma unit was extracted aseptically into a
clean bag for transfusion, leaving the platelet concentrate (in a
minimal volume of plasma). This was placed on a flat surface and
‘rested’ for 60 min at room temperature. The platelets were
thoroughly resuspended by gentle mixing. The buffy coat fraction
remained in the original collection bag. Red cells were
leucoreduced (using the inline T3953 filter) after separation from
whole blood. Platelet-rich plasma was first leucoreduced (using a
leucoreduction filter from the Fresenius/NPBI CompoStop F730
system), then separated into plasma and platelets by centrifugation
as described.
Determining the volume of each component transfused
Prior to transfusion, 10–20 ml of each component were sampled
for analysis and archive storage. After sampling was complete, the
volume of each component to be transfused was calculated by
subtracting the weight of an empty bag from the filled bag weight
and adjusting for weight (g)/volume (ml) by dividing by the
appropriate correction factor. We used specific gravities of 1.06 for
whole blood, red cell concentrate and buffy coat, and 1.03 for
plasma and platelets, as the correction factor for weight to volume
determinations.
Determining the distribution of plasma in components
The haematocrit (Hct) was used to determine the distribution
(%) of plasma in the separated components. A sample of whole
blood, red cells and buffy coat was drawn up into a plain glass
capillary and then one end capped. The capillary was centrifuged
for 6 min using a haematocrit centrifuge (Hawksley) and packed
cell volume measured using a haematocrit reader (Hawksley). We
used data provided by the Scottish National Blood Transfusion
Service to estimate the total volume of plasma in whole blood, and
then the percentage of the total plasma associated with red cell
concentrate, buffy coat, plasma unit and platelet concentrate (and
leucoreduced equivalents), following their preparation from whole
blood [34].
Leucocount analysis
Leucocytes in non-leucoreduced and leucoreduced blood
components were measured using a LeucocountTM kit (BD
Biosciences) in combination with flow cytometry. All leucode-
pleted samples were tested undiluted but non-leucodepleted
blood samples were first diluted in PBS, pH 7.4: whole blood and
red cell concentrates - 1: 500; buffy coat - 1:1000; plasma was
used neat and platelet concentrates diluted 1:30. In brief, 100 ml
of sample was added to TruCount tube which contained a known
number of 4.2 mm fluorescent beads. To this, 400 ml of
LeucocountTM reagent was added and samples were mixed and
incubated in the dark for 5 min, at room temperature. The assay
was validated using LeucocountTM combo quality control
samples, which were treated in the same way as blood samples.
A ‘blank’ was prepared by substituting 100 ml PBS, pH 7.4 in
place of the blood sample (bead control). All samples were
analysed using a 4-colour FACSCalibur (BD Biosciences). All test
samples were analysed after assay parameters were satisfied and
propidium iodide-stained cells were visualised in FL2 alone. From
statistical analysis, region statistics were obtained and the
leucocytes were enumerated using a simple calculation provided
by the manufacturer.
Platelet counting in plasma units and platelet
concentrates
Given the size difference between sheep and human platelets,
sheep samples could not be counted using a haematology analyser.
Therefore, samples from the platelet concentrate and plasma units
were first diluted (typically 1:300 and 1:7 respectively) in either
BARRS fluid (0.25% (w/v) saponin, 3.5% (w/v) sodium citrate
containing 1 ml of 40% (v/v) formaldehyde in a final volume of
100 ml distilled water, Sigma) or PBS, pH 7.4. Approximately
20 ml of diluted sample were used to fill a chamber of an improved
Neubauer haemocytometer. Platelets were visualised using640 or
6100 objectives and residual platelet numbers were counted using
standard techniques.
Results
BSE-infection status in animals used as blood donors
To date, 31 of the 39 infected donors have shown typical
clinical signs and pathological evidence confirming BSE infection,
with incubation periods ranging from approximately 534 to 1554
days (Figure 2). The incubation time may be influenced by a
variety of factors including variability in uptake of the infectious
agent following oral inoculation and the outbred genetic
background of the sheep. We anticipate that some additional
live BSE donors (n = 4) will develop disease, albeit with longer
incubation periods. Four BSE challenged donors culled at 258,
265, 320 and 683 days post infection, were confirmed as negative
for BSE (data not shown). One of ten mock-infected control
donors died of intercurrent causes (266 days post-inoculation) and
was confirmed negative for BSE infection. The survival period for
the remaining donors (control and infected) is greater than 1500
days.
Multiple Blood Components Transmit BSE
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Blood component preparation and specifications
The timing of blood collection from donors (in days post-
inoculation) is indicated by the horizontal bar in each column in
Figure 2. We aimed to prepare sheep blood components to the
same specifications as those used for human blood [34], using
similar processing methods and commercially available blood
packs and leucoreduction filters. This produced components of
whole blood (WB, n= 8), buffy coat (BC, n= 37) red cell
concentrates (RCC, n= 37), plasma (PLS, n = 38), platelet
concentrates (PLT, n= 37), leucoreduced red cell concentrates
(LR-RCC, n= 29), leucoreduced plasma units (LR-PLS, n= 29)
and leucoreduced platelet concentrates (LR-PLT, n= 29). The
components were transfused into TSE-free recipients (ARQ/ARQ
genotype, n = 244) over a periods of seven months. Nine units of
whole blood were prepared from mock-infected donors as negative
controls (Figure 1).
The majority of components prepared from sheep blood
matched the specifications for the same components prepared
from human blood. Similarities in the volumes of sheep and
human components were observed (Table S1-A), and for sheep
there was little change in component volume following leucor-
eduction (Figure 3A). In a clinical setting, leucoreduced compo-
nents must contain less than 16106 residual leucocytes per unit.
Figure 3B shows that LR-RCC, LR-PLS, LR-PLT, prepared from
sheep, contained 7.656104, 12.026103, and 0.916103 average
white cells/unit, respectively, and thus meet this criterion (Table
S1-B, Figure S1). Interestingly, non-leucoreduced plasma also
contained less than 16106 leucocytes per unit. Following
centrifugation, the majority of ‘whole blood plasma’ formed the
plasma unit, whilst the remainder differentially associated with red
cells (,15%), platelets (15–20%) and buffy coat (9%, Figure 3C).
The number of platelets associated with both non- and
leucoreduced plasma units contained less than ,306106/ml and
therefore met the specification required for the preparation of
human plasma units (Table S1-C). The specification for platelet
counts in human platelet concentrates was .606109 per unit. It
can be seen that several equivalents prepared from sheep blood
met this requirement, whilst others contained less than this
(ranging from 9–746109). For leucoreduced platelet concentrates,
the average platelet count was 16.23612.596109 (ranging from
0.35–416109, from 29 individual preparations, Figure 3D).
Platelets in all platelet concentrates were counted before and after
leucoreduction and we noted that in sheep the platelet count was
highly variable between animals, and that post-leucoreduction,
platelet counts were consistently lower (Figure 3D). Furthermore,
following extraction from platelet-rich plasma, aggregation of the
platelets occurred in some units (as assessed using microscopy)
which may have caused technical difficulties in counting, likely
resulting in an under-estimate of platelet counts.
All non-leucoreduced blood components can transmit
disease
We have demonstrated that all blood components, used in
routine transfusion medicine can support prion disease transmis-
sion by blood transfusion (Table 1).The volume transfused varied
between components (from ,50 ml volumes for buffy coat
compared to ,500 ml for whole blood units) and within
components (i.e. platelet volumes ranged from 44 to 74 ml). It is
important to remember that at the time of blood collection and
donation, all donors were healthy and not exhibiting clinical signs
of prion infection. Figure 2 highlights the donors from which
positive transmissions of BSE have occurred (grey bars). It is
conceivable that blood from some donors (though later confirmed
as having BSE) did not contain sufficient infectivity titres at the
time of donation to cause disease in transfused recipients. If this is
the case, not all transfused recipients will succumb to infection.
However, the positive transmissions observed here may provide a
basis for understanding the mechanism of prion replication in
blood, and subsequently the infection process. Our data also shows
that the clinical end point for any single component transfused was
different, which may be indicative of variable titres of infectivity
from donors themselves, or reflect how infectivity is distributed
amongst the separated components.
Following only a single blood transfusion to individual
recipients, we have observed 36 positive transmissions of BSE
following the transfusion of whole blood, red cell concentrate,
buffy coat, plasma and platelet concentrate prepared from
multiple donors. In some cases (Figure 4A) all non-leucoreduced
components prepared from a single donor were sufficiently
infectious to cause BSE in recipients (i.e. donor 2). Similar
outcomes were observed when the same repertoire of components
prepared from donors 7 and 16 were transfused to matched
recipients (Table 1). In other examples, only some of the non-
leucodepleted components transfused have resulted in disease in
recipients (i.e. red cell concentrate and buffy coat from donor 22
or buffy coat and platelets from donor 9). To date, whole blood
has shown the highest rate of transmission (37.5% of recipients
infected), followed by buffy coat (32.4%), platelets (24.3%), then
red cells (18.9%) and plasma (13.2%).
BSE was confirmed in recipients of non-leucodepleted compo-
nents, post-mortem, by the detection of PK-resistant PrPSc (a
marker for prion infection) by Western blotting assays or by
antibody staining of abnormal prion protein in tissue sections. A
range of tissues from each sheep were tested and included brain
and peripheral lymphoid tissues (spleen, tonsil, pre-scapular and
mesenteric lymph nodes). The PrPSc protein resolves, using SDS-
PAGE, as three separate protein bands which correlate to different
glycotypes. Figure 4B shows PrPSc in brain samples from recipients
of infected whole blood, red cells, plasma and platelet concentrates
(lanes 4, 5, 7, 8 and 9 respectively). The migration and protein
profile of the disease-associated prion protein resembles that of
cattle BSE as expected, (lane 1) and differs from that of sheep
affected with natural scrapie (lane 2). This data is confirmed by
Figure 2. Varied incubation times are seen in blood donors
following oral inoculation with BSE. All BSE-infected donor sheep
(apart from donor 4, which was culled for welfare reasons) were culled
on demonstration of clinical signs. The range of incubation period for
sheep confirmed as having BSE is 534–1544 days post infection (dpi).
The horizontal bar in each column represents the time of blood
collection for separation and subsequent transfusion to recipients and
ranges from 228–463 days post oral inoculation. To date, 31/39 donors
have succumbed to BSE infection and the grey bars indicate donor
blood, which when transfused, caused disease in recipients.
doi:10.1371/journal.pone.0023169.g002
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further biochemical processing which removes the carbohydrates
from the PrPSc protein, leaving only a single protein band
(Figure 4C), whereby the BSE motif in transfused sheep becomes
more obvious, resulting in the lower apparent molecular weight of
the unglycosylated protein band compared to sheep scrapie. Brain
and lymphoid follicles of the tonsil, from donor 16, also showed
abnormal prion protein deposition, following antibody staining
and immunohistochemical analysis (Figures 4D and E respective-
ly). In a limited number of cases, sheep were culled before the
onset of clinical signs and for other health reasons. This provided
an opportunity to examine the distribution of PrPSc in different
brain regions and peripheral tissues in sheep pre-clinically affected
with BSE (Figures S2A–S2C).
Leucoreduction of blood components does not prevent
prion disease transmission via blood transfusion
Currently, we have observed transmissions of BSE following the
transfusion of leucoreduced-red cells (Table 1; donors 13 and 19), -
plasma and -platelets (donor 13). Figure 5A shows that all blood
components prepared from donor 13 contained sufficient
infectivity titres to cause BSE in transfused recipients. However,
the striking observation was that even after leucoreduction,
infectivity titres were still sufficient to transmit BSE. To date, in
nearly all cases, little or no difference in the incubation period was
seen in recipients of paired non-leucoreduced plasma and red cells
and their leucoreduced equivalents (Figure 5A). This was mirrored
in the comparable BSE-like protein profiles in brain of donor 13
and respective recipients’ that received plasma, red cells and
leucoreduced equivalents (Figure 5B). The same profile was
detected in brain of recipient 13-G (not shown). However, for
paired platelets and leucoreduced platelet recipients (13-D and 13-
G respectively, Table 1), there is a difference of some 700 days in
incubation time. Both of these recipients, whilst demonstrating
intermittent, early clinical signs of BSE infection, were culled
because of underlying welfare issues and so the true incubation
period, i.e. the time between infection to clinical disease, are not
accurately reflected by the cull dates. Indeed in the case of
recipient 13-D (platelets), PrPSc was only detected in the spleen
and pre-scapular lymph node, but not in brain (Figure S2-C)
suggesting an early stage of infection and peripheral pathology.
Leucoreduced-red cell concentrate from donor 19 also trans-
mitted BSE following transfusion to recipient 19-A (Figure 5C),
though in an apparently shorter time frame than red cells alone.
BSE was confirmed by the characteristic PrPSc profile in brain of
donor 19 and its respective culled recipients (data not shown).
Recipients that received leucoreduced-plasma and -platelets from
donor 19 are still healthy and to date are not demonstrating
clinical signs associated with BSE infection. In relation to the
number of each type of leucoreduced component transfused,
leucoreduced-red cells have shown the higher rate of transmission
(6.9% of recipients infected), compared to 3.4% for both
Figure 3. Analysis of sheep blood components. Graph A shows the range and average volume (61SD) of each component used for transfusion.
No difference was observed in the volume between leucoreduced (grey bars) and non-leucoreduced components (black bars). White cell counts were
calculated using LeucocountTM kits and flow cytometry. All leucoreduced components from sheep (grey bars) meet the specifications assigned to
human equivalents and contained less that 16106 residual leucocytes (as shown by the solid line, graph B). Following the separation of whole blood,
the majority of the total plasma volume was distributed in association with plasma unit. The remaining plasma volume was differentially distributed
in red cells, platelets and buffy coat, (panel C) as a percentage of the total plasma volume. No major differences were observed in plasma distribution
between leucodepleted and non-leucodepleted components. The number of platelets in platelet concentrates prepared from leucoreduced and non-
leucoreduced components was highly variable in sheep and the average count was statistically significantly different (p,161025, using 2-tailed
Student’s t-test, graph D).
doi:10.1371/journal.pone.0023169.g003
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leucoreduced-plasma and -platelets (Table 2). However, these data
represent interim transmission efficiencies and will likely change
over the full time-course of the study. The survival period for the
remaining recipients (control and infected) is greater than 1200
days
Prion infectivity in blood is present early in the pre-
clinical phase of disease
The marked variability in incubation period observed in donor
sheep following oral BSE infection was not anticipated (Figure 2).
Given that we collected blood from donors around 200–400 days
post-oral BSE infection, this provided an opportunity to examine
the prion-associated infectivity in blood at different pre-clinical
stages of disease. Extrapolation of our data shows that blood
collected from confirmed BSE-infected donors at intervals
between 27–61% of the incubation period is infectious (Table
S2). For example, donor 5 was first inoculated with BSE (day 0);
then 228 days later two units of blood were collected, processed
and components transfused to recipients. This donor started to
show clinical signs of BSE approximately 914 days after BSE
infection and, following a short clinical phase, was euthanized.
Prion-associated infectivity in this donor’s blood was confirmed by
transmission of BSE to transfused recipients, even though the
donor was healthy and there was no clinical evidence to suggest
prion disease at the time of blood donation. We calculated the
timing of the blood donation and onset of clinical signs as a
function of the final incubation period (i.e. date of euthanasia). We
observed that infectivity in blood is present very early in the
incubation period, with positive transmissions occurring from
blood collected as early as 27% of the final incubation period
(Table S2), which is earlier then previously reported [27,35].
These are individual collections from each sheep, and not a true
time course experiment. We cannot therefore conclude whether
blood from donors 2, 7 and 16, collected at time points earlier than
51, 57 and 61% of the incubation period respectively, contained
the same or different titres of infectivity and hence, if transfused,
would result in BSE. It should also be noted that, in general, blood
collected from the sheep with shorter incubation periods (,650
days, i.e. donors 2, 6, 7, 13, 14, 16, 19, 22 and 24) have
transmitted BSE to a greater number of recipients than those
donors with longer incubation periods (i.e. donors 1, 5, 9 and 21).
This may reflect the levels of infectivity in the blood at the time of
collection and donation [27].
Discussion
We have shown that all of the blood components investigated,
whole blood, plasma, red cells, platelets and buffy coat, are
capable of transmitting BSE infection following transfusion into
susceptible sheep. Although infectivity has consistently been
detected in plasma in rodent scrapie models, this is the first time
that transmission of prion disease has been demonstrated following
transfusion of plasma units collected from pre-clinical donors, and
prepared to the same specifications as non-fractionated human
plasma. While the results with platelets and leucocytes are similar
Table 1. Summary of BSE transmissions in recipients
following blood transfusion.
Donors (D) Recipients (R)
ID
Component
donated
Volume Transfused
(ml) ID Cull (dpt)
D1 BC 92 R1-A* 631
D2 WB 358 R2-A 567
RCC 300 R2-B{ 616
BC 25 R2-C 639
PLS 185 R2-D 594
PLT 46 R2-E 741
D5 PLT 74 R5-A 1001
D6 PLT 60 R6-A 701
BC 44 R6-B 701
D7 WB 514 R7-A 792
RCC 301 R7-B{{ 658
BC 41 R7-D 904
PLS 185 R7-E 953
PLT 50 R7-C 609
D9 BC 46 R9-B 595
PLT 44 R9-A 643
D13 RCC 307 R13-A 1008
BC 45 R13-B 513
PLS 164 R13-C 720
PLT 60 R13-D{ 391
LR-RCC 324 R13-E 1008
LR-PLS 121 R13-F 770
LR-PLT 45 R13-G{ 1120
D14 BC 63 R14-A 1146
D16 WB 555 R16-A 468
RCC 287 R16-B 987
BC 36 R16-C* 603
PLS 173 R16-D 1089
PLT 62 R16-E 974
D19 RCC 299 R19-B 841
BC 28 R19-C 878
PLT 45 R19-D 995
LR-RCC 243 R19-A 681
D21 BC 55 R21-A 784
D22 RCC 269 R22-A 1063
BC 43 R22-B 821
D24 RCC 254 R-24C 1105
BC 52 R24-A 729
PLS 203 R24-D* 652
PLT 55 R24-B 1016
*indentifies animals that were culled because of inappetance, which we now
recognise to be an early symptom of TSE infection occuring before overt clinical
signs.
{indicates animals that were culled for other welfare, non-TSE causes.
{{This animal died of intercurrent causes.
Table 1 shows details of blood components which, when transfused from
donors to paired recipients, have resulted in BSE. The time point of euthanasia
in recipients is indicated in days post transfusion (dpt) and animals were culled
following presentation of clinical signs typical of BSE. In a limited number of
cases, sheep were culled for welfare reasons. Transfused components are
abbreviated as follows: whole blood (WB), red cell concentrates (RCC), buffy
coat (BC), plasma (PLS), platelet concentrates (PLT) and leucoreduced
equivalents are prefixed with ‘LR’. The volume of each component the
recipients received is indicated in ml.
doi:10.1371/journal.pone.0023169.t001
Table 1. Cont.
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to that of Mathiason et al. [30], the plasma results are strikingly
different. In the previous study, prion infected cell-free plasma
appeared not to cause disease following transfusion in deer. The
reason for this is not clear and may relate to either a difference in
the distribution of PrPSc and/or infectivity in different host species
or indeed the strain of infectious agent used.
We also observed a number of cases in which leucoreduced
components have caused BSE in recipients following transfusion.
Other recipients of leucoreduced components are also now
Figure 5. BSE is transmitted following the transfusion of
leucoreduced components. Panel A shows the entire repertoire of
components prepared from donor 13 (D13) and transfused. The
corresponding incubation periods (defined as the date of death based
on reaching defined clinical endpoints) is shown in days above the bars.
Both platelet recipients (R13-D and R13-G) did not reach clinical
endpoint, but were culled for welfare reasons (thus these ‘incubation
periods’ correctly refer to the date of euthanasia, in days post
transfusion (dpt)). Panel B is a representative immunoblot showing
PrPSc in brain samples of donor 13 (lane 1) and selected, matched
transfusion recipients of buffy coat, leucoreduced plasma, red cells,
plasma and leucoreduced red cells (lanes 2–6 respectively), thus
confirms BSE infection following the transfusion of leucoreduced blood
components. Selected recipients of components, including leucore-
duced red cells, from donor 19 were also confirmed to have BSE. All of
these recipients developed a clinical disease at different time points
post transfusion (panel C). Blood from donors 13 and 19 was collected
at 48 and 52% of the final incubation period respectively; all later
showed typical clinical signs of BSE and were confirmed as positive, as
previously described.
doi:10.1371/journal.pone.0023169.g005
Figure 4. Confirmation of BSE in recipients of non-leucore-
duced components. Panel A shows the incubation periods of donor 2
(D2) and its respective transfusion recipients of whole blood (R2-A), red
cells (R2-B), buffy coat (R2-C), plasma (R2-D) and platelets (R2-E),
whereby the nomenclature used to describe sheep is consistent with
that in Table 1. Panel B shows PrPSc in brain from a donor and a range of
transfusion recipients compared to PrPSc in experimental controls. Lane
1 – BSE control, lane 2 – sheep scrapie control, lane 3 – donor 2, lane 4
whole blood recipient, lanes 5 and 6 – two recipients of red cells, lane 7
– plasma recipient and lanes 8 & 9 – two recipients of platelets. Lane 6
shows detection of low levels of PrPSc in recipient 7B that received a
unit of red cell concentrate and died of intercurrent causes before
reaching clinical endpoints. The PrPSc profile is consistent with that of
cattle BSE (lane 1) as expected. These data are confirmed following
PNGase F treatment of PrPSc as shown in panel C. Panels D and E show
abnormal prion protein deposition in dorsal motor nuclei of the vagus
nerve (DMNV) in brain and tonsil of donor 16, respectively. Tissue
sections were stained with BG4.
doi:10.1371/journal.pone.0023169.g004
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showing early signs of TSE infection and we would therefore
expect more positive transmissions of BSE from these components.
These data demonstrate that leucoreduction of blood components
alone is insufficient to prevent transmission of prion infection via
blood transfusion [23]. All four of the documented transfusion-
related transmissions of vCJD infectivity to date have occurred in
individuals who received red cells (the most commonly transfused
blood component) which were non-leucoreduced, between 1996
and 1999. Eighteen surviving recipients [36] transfused with red
blood cells (n = 6), cryodepleted plasma (n = 1) and leucoreduced
red blood cells (n = 11) from donors who were subsequently
confirmed to have vCJD are still being followed up (personal
communication from Miss J. McKenzie and Prof. R.G. Will,
TMER study). There are a small number of cases of clinical vCJD
with a history of blood transfusion, where no donor has developed
clinical vCJD but where transfusion remains the possible source of
infection. The most recent of these cases (2002) received
leucoreduced red cells. Our findings would suggest that residual
infectivity following leucoreduction may still pose a risk of
transmission in a transfusion setting [23,37,38].
These transfusion studies were conducted in sheep, in which
many effects of polymorphisms associated with the prnp gene
(which modulates susceptibility to prion infection) are well
understood. Similarly, the age at which donors and recipients
were exposed to BSE prions, the infectious dose (in donor sheep)
and the route of infection were relatively well controlled. Despite
the control of known variables within this experiment, we observed
significant variability in the incubation period of both orally
infected donors and transfused recipients. During the course of this
study we identified a novel effect of an existing polymorphism in
the sheep PRNP gene, which modulates the incubation period of
orally infected BSE donors (unpublished observations). While
some of the variability in incubation periods of transfused
recipients is likely associated with other genetic factors
[39,40,41], it is also likely to be influenced by variability in prion
titre in blood from donor sheep. It must also be recognised that in
this model, incubation period is not considered an indicator of titre
of infectivity in blood, since a full titration of infected blood has not
yet been undertaken in sheep. However, given that BSE occurred
in recipients following a single blood transfusion from donors who
were healthy at the time of blood donation, we would suggest that
even when or if the infectious load is low, disease can result if the
route of transmission, i.e. blood transfusion, is highly efficient.
Whilst we have clearly shown that blood collected from donor
animals at a single time point is infectious, what remains unclear is
when prion-associated infectivity first appears in blood, how it
relates to incubation period and how the titre of infection changes
as disease progresses. We are investigating these questions by
inoculating transgenic mice with blood collected at various time
points throughout the incubation period, from the same donor
sheep as used in this study. This will allow us to address the
duration, pattern and titre of prion infectivity in blood.
Our data raises considerable questions concerning the distribu-
tion of infectivity in blood, including its potential association with
cell types other than leucocytes i.e. red cells and platelets, and/or
other proteins or soluble components of plasma. Our data relating
to the current transmission efficiencies of each component suggest
whole blood and buffy coat represent the greatest risk in terms of
transfusion and blood safety. However, these data may change
over the full time course of this study and therefore it is too early to
draw definitive conclusions. Furthermore, the blood components
used in this study (including leucoreduced equivalents) were not
purified cell populations, but also contained plasma and leucocytes
to reflect the nature of the components routinely transfused in
human patients. This may complicate understanding the process
of identifying the relationship between the infectious agent and cell
targets. It is also possible that mechanisms such as release of
membrane fractions during processing [42] or shedding/transit by
plasma membrane-derived microvesicles [43,44] may also con-
tribute to the dissemination of infectivity in blood. It will be critical
to understand how prion infectivity associates with particular
blood components, and may identify new targets for diagnostics,
therapeutics and allow for more refined risk reduction strategies.
Whilst these findings highlight the difficulties in predicting
incubation times and the clinical outcomes associated with
transfusion-related transmission of vCJD in humans (because of
the extensive variability of individuals in terms of age, genetic
background, titre and route by which one could be exposed) these
data have clear implications for transfusion practices. We
demonstrate the potential risk of acquiring vCJD from any blood
component used in routine transfusion medicine, following a single
transfusion from asymptomatic individuals.
While there has been recent, significant, developments in the
quest for a blood-based assay to detect prion infection in
symptomatic individuals [45], implementing such assays in the
blood transfusion service to detect asymptomatic donors requires
Table 2. Current transmission efficiencies of blood components.
Challenge No. animals inoculated No. BSE +ve sheep Transmission efficiency
Donors 5 g BSE brain 39 31 79%
Recipients Whole blood 8 3 37.5%
Red cells 37 7 18.9%
Buffy coat 37 12 32.4%
Plasma 38 5 13.2%
Platelets 37 9 24.3%
LR-Red cells 29 2 6.9%
LR-Plasma 29 1 3.4%
LR-Platelets 29 1 3.4%
Table 2 identifies the number of positive transmissions of BSE, by the component transfused to recipients. The current transmission efficiency of each type of blood
component was determined by calculating the number of recipients confirmed as having BSE (post-mortem) as a percentage of the total number of each component
transfused. The attack rate for orally infected BSE donor sheep is shown for comparison. Blood components prefixed by ‘LR’ mean that they were leucoreduced prior to
transfusion.
doi:10.1371/journal.pone.0023169.t002
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extensive validation. Thus there currently remains the potential for
human to human transmission of vCJD via blood transfusion from
individuals carrying the infectious agent but not showing clinical
signs of disease. Our data suggests that leucoreduction alone is
inadequate to minimise the risk of transmission of vCJD and to
ensure the safety of blood used in transfusions and ultimately to
safeguard public health.
Supporting Information
Figure S1 Enumeration of leucocytes in transfused
components using flow cytometry. Leucocount reagent
(BD Bioscience) was used to measure white cell counts in both
leucoreduced and non-leucoreduced components, though non-
leucoreduced components were first diluted before analysis. White
cells are stained with propidium iodide (PI, shown in gate 2 in all
dot plots). Absolute enumeration is achieved by comparing PI-cell
staining against a known number of fluorescent beads (gate 1 in all
dot plots) and sample volume assayed. The performance
characteristic of the assay is calibrated against kit controls (panels
B-E), including the bead control (panel A). Panels F, G and H
show PI-stained leucocytes in red cell concentrates, plasma and
platelet concentrates respectively. Following leucoreduction, little
or no events were recorded in gate 2, indicating a gross reduction
in the number of white cells contained in leucoreduced-red cells
(panel I), plasma (panel J) and platelets (panel K). A simple
calculation (provided by the manufacturers) is used to determine
the leucocyte count, from those samples in which events in gate 2
were recorded.
(TIF)
Figure S2 A: PrPSc distribution at the end stage disease.
At the clinical endpoint PrPSc is deposited in all brain regions and
peripheral tissues from recipient 2-D, which received a unit of
plasma from donor 2. Lane annotations are: 1 - Frontal cortex, 2
– Cerebellum, 3 – Thalamus, 4 – Midbrain, 5 – Pons, 6 –
Medulla, 7 - Spinal cord, 8 – Spleen, 9 – Tonsil,10 - Distal ileal
Peyers Patch, 11 - Mesenteric lymph node,12 - Pre-scapular
lymph node. B: PrPSc distribution in an animal that died
from intercurrent causes. Recipient 7-B (which received a
unit of red cell concentrate from donor 7) died of intercurrent
causes 658 days after transfusion and before demonstrating
clinical signs of BSE infection. PrPSc was detected in the spleen of
this recipient and lower levels in the pre-scapular lymph node. In
brain, PrPSc was first detected in the medulla suggesting that
PrPSc may be routed to the brain from the periphery, via the
peripheral and autonomic nervous system, as reported by others
[46,47,48,49,50]. Alternative routes of entry of BSE infection
from blood directly into the brain have also been described
[51,52,53]. Lane annotations are: 1 - Frontal cortex, 2 –
Cerebellum, 3 – Thalamus, 4 – Midbrain, 5 – Pons, 6 –
Medulla, 7 - Spinal cord, 8 – Spleen, 9 – Tonsil,10 - Distal ileal
Peyers Patch, 11 - Mesenteric lymph node,12 - Pre-scapular
lymph node. C: PrPSc distribution in an animal culled for
welfare reasons. Recipient 13-D, received a unit of platelet
concentrate from donor 13, and was culled on the basis of health
concerns combined with early clinical signs, only 391 days after
being transfused. In this case, the spleen and pre-scapular lymph
node were the only lymphoid tissues which showed PrPSc
reactivities. Previous studies have shown PrPSc deposition in
tonsil following transfusion of BSE-infected blood [33,54]. The
differences observed in these studies are likely related to
differences in the stage of infection at which the sheep were
culled and tissues examined. Hence, our current data may suggest
that tonsil is an unreliable indicator for early stages of TSE
infection acquired by blood transfusion. PrPSc was not detected in
the medulla (data not shown). Lane annotations are: 8 – Spleen, 9
– Tonsil,10 - Distal ileal Peyers Patch, 11 - Mesenteric lymph
node,12 - Pre-scapular lymph node.
(TIF)
Table S1 A: Volume of blood components transfused to
sheep compared to human components. Table S1-A shows
that the average volume, (ml)61SD, of each component prepared
from BSE-infected sheep blood is within the normal specifications
for the same components prepared from human blood. Whole
blood (WB), red cell concentrate (RCC), plasma (PLS), platelets
(PLT). Leucoreduced equivalents are pre-fixed with ‘LR’. *Note
that buffy coat (BC) is not a product that is transfused (without
further processing by the blood transfusions services). The
volumes of platelets and plasma units used by the blood
transfusion services are arbitrarily estimated, as the critical
specifications for these components are the numbers of platelets
that they contain as opposed to a specific volume prepared. The
average volume for control whole blood transfused (n = 9) was
493 ml69. B: Leucocount analysis. Table S1-B shows that all
leucodepleted components used in our transfusion studies meet
the same criteria as human equivalents and contain less than
16106 white blood cells per unit. The greatest concentration of
white cells, following the separation of whole sheep blood, was
associated with red cell concentrates and buffy coat, then
distributed to a lesser extent within plasma and platelets. C:
Platelet analysis. Table S1-C shows that the values obtained
for platelet units were less than the specification recommended
for human platelet units. This is likely due to platelets being
trapped in the leucoreduction filters. It is important to note that
sheep platelet units were not administered for medicinal purposes
but were transfused in our study for qualitative comparisons of
infectivity in blood components. The residual platelet concentra-
tion was, however, enriched 20 to 30-fold in leucoreduced and
non-leucoreduced platelet concentrates compared to plasma unit
equivalents respectively (data not shown).
(DOC)
Table S2 Blood collection from donors as function of
incubation time. BSE infected donor sheep were first infected
with 5 g BSE after which blood was collected. We aimed to collect
blood for transfusion from donors about 50% (,300–350 days) of
the way through the final incubation period (based on estimates of
clinical disease occurring between 20–22 months (600–720 days)
post oral infection, hence when sheep would still be healthy and
asymptomatic of BSE infection. We have observed positive
transmissions of BSE from donors 1, 2, 5, 6, 7, 9, 13, 16, 19, 21
and 24 (bold and underlined). From this, we have observed for the
first time using this model, that blood for BSE infected donors
contains significant levels of infectivity from as early as 24% of the
way through the final incubation time (donor 5) to 61% of the final
incubation period (donor 16).
(DOC)
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